FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808027013> ?p ?o ?g. }

• W2808027013 endingPage "662" @default.
• W2808027013 startingPage "655" @default.
• W2808027013 abstract "This study is to investigate transcription factors involved in cisplatin resistance in ovarian cancer cells. The transcriptome of cisplatin resistant and sensitive A2780 epithelial ovarian cancer cells was obtained from GSE15372. Ovarian transcriptome data GSE62944 was downloaded from TCGA and applied for transcription regulatory network analysis. The analysis results were confirmed using quantitative polymerase chain reaction. The roles of SREBP2 in cisplatin-resistant cells were investigated by RNA inference and cell viability analysis. Transcription regulatory network analysis found that 12 transcription factors and their targets were involved in cisplatin resistant in A2780 cells. Among these factors, the targets of EZH2 and SREBP2 revealed by Transcriptional Regulatory Relationships Unraveled by Sentence-based Text mining were also enriched in differentially expressed genes between cisplatin resistant and cisplatin sensitive cells. Their targets were enriched mainly in cell cycle and cholesterol metabolic process, respectively. Bioinformatic analysis illustrated three known targets of SREBP2, namely LDLR, FDFT1, and HMGCR were increased in A2780-resistant cell lines. Additionally, the three genes and SREBP2 were also elevated in live cells after cisplatin treatment via quantitative polymerase chain reaction. Importantly, RNA inference of SREBP2 in A2780 cell line resulted in a decrease of cell viability after cisplatin treatment. SREBP2 played important roles in cisplatin resistance and cholesterol metabolic process might be a novel target for cancer therapy. Impact statement Transcriptome of cisplatin resistant and sensitive A2780 epithelial ovarian cancer cells was obtained from GSE15372 and TCGA. Twelve transcription factors and their targets were involved in cisplatin resistant. Among these factors, the targets of EZH2 and SREBP2 revealed by Transcriptional Regulatory Relationships Unraveled by Sentence-based Text mining were also enriched in differentially expressed genes. Their targets were enriched mainly in cell cycle and cholesterol metabolic process. Three targets of SREBP2, namely LDLR, FDFT1, and HMGCR were increased in A2780-resistant cell lines and were found elevated in live cells after cisplatin treatment via qPCR. RNAi of SREBP2 in A2780 cell line resulted in a decrease of cell viability after cisplatin treatment. SREBP2 played important roles in cisplatin resistance and might be a novel target for cancer therapy." @default.
• W2808027013 created "2018-06-21" @default.
• W2808027013 creator A5016945454 @default.
• W2808027013 creator A5027475930 @default.
• W2808027013 creator A5060309212 @default.
• W2808027013 creator A5064707086 @default.
• W2808027013 creator A5077779563 @default.
• W2808027013 date "2018-02-22" @default.
• W2808027013 modified "2023-10-18" @default.
• W2808027013 title "SREBP2 contributes to cisplatin resistance in ovarian cancer cells" @default.
• W2808027013 cites W2015708085 @default.
• W2808027013 cites W2020681708 @default.
• W2808027013 cites W2022853846 @default.
• W2808027013 cites W2052543023 @default.
• W2808027013 cites W2058916559 @default.
• W2808027013 cites W2063764833 @default.
• W2808027013 cites W2073513329 @default.
• W2808027013 cites W2086241979 @default.
• W2808027013 cites W2086453930 @default.
• W2808027013 cites W2096173332 @default.
• W2808027013 cites W2102346197 @default.
• W2808027013 cites W2107277218 @default.
• W2808027013 cites W2115420718 @default.
• W2808027013 cites W2115954319 @default.
• W2808027013 cites W2122340896 @default.
• W2808027013 cites W2130879249 @default.
• W2808027013 cites W2146512944 @default.
• W2808027013 cites W2155736495 @default.
• W2808027013 cites W2156730318 @default.
• W2808027013 cites W2177194315 @default.
• W2808027013 cites W2192080449 @default.
• W2808027013 cites W2197184744 @default.
• W2808027013 cites W2198703760 @default.
• W2808027013 cites W2235523093 @default.
• W2808027013 cites W2272984102 @default.
• W2808027013 cites W2277202206 @default.
• W2808027013 cites W2277854123 @default.
• W2808027013 cites W2328421677 @default.
• W2808027013 cites W2398889007 @default.
• W2808027013 cites W2511245997 @default.
• W2808027013 cites W2511319937 @default.
• W2808027013 cites W2582729774 @default.
• W2808027013 cites W2592717780 @default.
• W2808027013 cites W2606203776 @default.
• W2808027013 cites W2607788676 @default.
• W2808027013 cites W2772682581 @default.
• W2808027013 cites W2895065487 @default.
• W2808027013 cites W65570626 @default.
• W2808027013 doi "https://doi.org/10.1177/1535370218760283" @default.
• W2808027013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6582395" @default.
• W2808027013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29466876" @default.
• W2808027013 hasPublicationYear "2018" @default.
• W2808027013 type Work @default.
• W2808027013 sameAs 2808027013 @default.
• W2808027013 citedByCount "31" @default.
• W2808027013 countsByYear W28080270132018 @default.
• W2808027013 countsByYear W28080270132019 @default.
• W2808027013 countsByYear W28080270132020 @default.
• W2808027013 countsByYear W28080270132021 @default.
• W2808027013 countsByYear W28080270132022 @default.
• W2808027013 countsByYear W28080270132023 @default.
• W2808027013 crossrefType "journal-article" @default.
• W2808027013 hasAuthorship W2808027013A5016945454 @default.
• W2808027013 hasAuthorship W2808027013A5027475930 @default.
• W2808027013 hasAuthorship W2808027013A5060309212 @default.
• W2808027013 hasAuthorship W2808027013A5064707086 @default.
• W2808027013 hasAuthorship W2808027013A5077779563 @default.
• W2808027013 hasBestOaLocation W28080270132 @default.
• W2808027013 hasConcept C104317684 @default.
• W2808027013 hasConcept C121608353 @default.
• W2808027013 hasConcept C1491633281 @default.
• W2808027013 hasConcept C150194340 @default.
• W2808027013 hasConcept C162317418 @default.
• W2808027013 hasConcept C2776694085 @default.
• W2808027013 hasConcept C2778239845 @default.
• W2808027013 hasConcept C2780427987 @default.
• W2808027013 hasConcept C29537977 @default.
• W2808027013 hasConcept C502942594 @default.
• W2808027013 hasConcept C53227056 @default.
• W2808027013 hasConcept C54355233 @default.
• W2808027013 hasConcept C86339819 @default.
• W2808027013 hasConcept C86803240 @default.
• W2808027013 hasConcept C95444343 @default.
• W2808027013 hasConcept C96232424 @default.
• W2808027013 hasConceptScore W2808027013C104317684 @default.
• W2808027013 hasConceptScore W2808027013C121608353 @default.
• W2808027013 hasConceptScore W2808027013C1491633281 @default.
• W2808027013 hasConceptScore W2808027013C150194340 @default.
• W2808027013 hasConceptScore W2808027013C162317418 @default.
• W2808027013 hasConceptScore W2808027013C2776694085 @default.
• W2808027013 hasConceptScore W2808027013C2778239845 @default.
• W2808027013 hasConceptScore W2808027013C2780427987 @default.
• W2808027013 hasConceptScore W2808027013C29537977 @default.
• W2808027013 hasConceptScore W2808027013C502942594 @default.
• W2808027013 hasConceptScore W2808027013C53227056 @default.
• W2808027013 hasConceptScore W2808027013C54355233 @default.
• W2808027013 hasConceptScore W2808027013C86339819 @default.
• W2808027013 hasConceptScore W2808027013C86803240 @default.

• next